Persistence and Adherence to Low-Dose Aspirin for Primary and Secondary Prevention of Cardiovascular DiseasE Using OHDSI
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 99,999
- 试验地点
- 1
- 主要终点
- Adherence to low-dose aspirin
研究概览
简要总结
This study aims to gather information to what extent patients follow the treatment regimen of low-dose aspirin for primary and secondary prevention of diseases of the heart and blood vessels. Researcher will collect information about the percentage of time a patient has access to the medication, how long patients continue with the medication and of the proportion of patients who switch from dual-antiplatelet therapy (including low-dose aspirin) to a single antiplatelet therapy. The study will make use of secondary healthcare data sources converted in to Observational Medical Outcomes Partnership (OMOP) common data model within the Observational Health Data Sciences and Informatics (OHDSI) network.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged ≥18 years
- •Patients will be selected if they have at least two prescriptions for low-dose aspirin (75-100 mg) between 2008 and 2018 for either:
- •Primary prevention of CVD This is defined as patients who have no history of CVD any time prior to initiation of low-dose aspirin treatment are presumed to use for primary CVD prevention
- •Secondary prevention of CVD This is defined as patients who have a history of CVD any time prior to initiation of low-dose aspirin treatment
- •Patients with at least two prescriptions of low-dose aspirin with a dosage of 75-100mg within the first year of the index date.
- •Restricted to patients with observation for at least 12 months before and 12 after the index date.
排除标准
- •Prescription of low-dose aspirin in 12 months before the index date.
研究组 & 干预措施
Low-dose aspirin users
Patients who receive low-dose aspirin (75-100mg) for either the primary or secondary prevention of cardiovascular disease (CVD).
干预措施: Acetylsalicylic Acid (Aspirin, BAYE4465) (Drug)
结局指标
主要结局
Adherence to low-dose aspirin
时间窗: Retrospective analysis from 2007 to 2018
Adherence low-dose aspirin use will be represented by the medication possession ratio (MPR)
Persistence to low-dose aspirin
时间窗: Retrospective analysis from 2007 to 2018
In terms of continuation and discontinuation: * Continuation at 30 and 60 day gaps * Discontinuation: * If patients switched to another antiplatelet therapy * If patients reinitiated low-dose aspirin \>30 days and \>60 days after end of supply i.e. of the pre-specified gap was exceeded * If patients stopped low-dose aspirin therapy completely
次要结局
- Time to switch from dual-antiplatelet to a monotherapy(Retrospective analysis from 2007 to 2018)